Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 7/20 | 0.41 |
| ▸ | NNMT | P40261 | 5/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321604 | 0.75 | SLC2A1 (0.63) | SLC2A1PARP1NNMTRXFP1PIM1 | |
| SCHEMBL4625947 | 0.74 | SLC2A1 (0.77) | SLC2A1PARP1NNMTPIM1TTK | |
| SCHEMBL7622343 | 0.74 | SLC2A1 (0.50) | SLC2A1PARP1NNMTPIM1TTK | |
| SCHEMBL2483995 | 0.72 | NPSR1 (0.50) | SLC2A1PARP1NNMTNPSR1RXFP1 | |
| SCHEMBL5464747 | 0.70 | SLC2A1 (0.56) | SLC2A1NNMTRXFP1MEN1KMT2A | |
| SCHEMBL15054260 | 0.70 | SLC2A1 (0.47) | SLC2A1PARP1NNMTNPSR1RXFP1 | |
| SCHEMBL17646064 | 0.70 | SLC2A1 (0.50) | SLC2A1PARP1NNMTNPSR1RXFP1 | |
| SCHEMBL3965438 | 0.70 | SLC2A1 (0.47) | SLC2A1PARP1NNMTPDE4B | |
| SCHEMBL31251385 | 0.70 | KMT2A (0.59) | MEN1KMT2APOLB | |
| SCHEMBL12876619 | 0.69 | SLC2A1 (0.46) | SLC2A1NNMTPIM1TTKPIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270444-A1 | 1,7-Naphthyridines | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270444-A1 | 1,7-Naphthyridines | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | disclosed |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | disclosed |
| EP-1866305-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| EP-1812434-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006097340-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097340-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006053784-A2 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | PDE4A, PDE3B, PDE4B | SLC2A1 3875/4885PARP1 1580/4885NNMT 83/4885 |
| US-20090270444-A1 | 1,7-Naphthyridines | CYP2F1, CYP2S1, CYP1A1 | SLC2A1 1779/4885PARP1 1391/4885NNMT 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.